目的 探討腸炎寧糖漿聯(lián)合奧替溴銨片治療腸易激綜合征的臨床療效。方法 選取2019年4月-2020年8月河南醫(yī)學(xué)高等?？茖W(xué)校附屬醫(yī)院收治的92例腸易激綜合征患者為研究對(duì)象，根據(jù)隨機(jī)數(shù)字表法將92例分為對(duì)照組和治療組，每組各46例。對(duì)照組口服奧替溴銨片，40 mg/次，3次/d。治療組在對(duì)照組基礎(chǔ)上口服腸炎寧糖漿，10 mL/次，3次/d。兩組患者連續(xù)治療4周。觀察兩組的臨床療效，比較兩組的腹痛、腹脹、腹瀉消失時(shí)間，腸易激綜合征的特征指數(shù)生活質(zhì)量量表（IBS-QOL）評(píng)分和血清中白細(xì)胞介素-6（IL-6）、白細(xì)胞介素-18（IL-18）、神經(jīng)肽Y（NRY）、血管活性腸肽（VIP）、膽囊收縮素（CCK）、胃動(dòng)素（MTL）水平。結(jié)果 治療后，治療組患者的總有效率為93.48%，對(duì)照組的總有效率為78.26%，組間有明顯差異（P<0.05）。治療后，治療組患者腹痛、腹脹、腹瀉消失時(shí)間均比對(duì)照組短（P<0.05）。治療后，兩組患者的IBS-QOL評(píng)分明顯升高，差異有統(tǒng)計(jì)學(xué)意義（P<0.05）；且治療組患者IBS-QOL評(píng)分升高的更明顯，差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組的IL-6、IL-18水平明顯降低，NRY水平明顯升高（P<0.05）；且治療后治療組的IL-6、IL-18水平低于對(duì)照組，NRY水平高于對(duì)照組（P<0.05）。治療后，兩組的CCK水平明顯升高，VIP、MTL水平明顯降低（P<0.05）；且治療后治療組的CCK水平比對(duì)照組高，VIP、MTL水平低于對(duì)照組，差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。結(jié)論 腸炎寧糖漿聯(lián)合奧替溴銨片可提高腸易激綜合征的臨床療效，改善臨床癥狀，增強(qiáng)患者的生活質(zhì)量，減輕炎癥反應(yīng)，調(diào)節(jié)胃腸激素，安全性良好。

Objective To investigate the clinical effect of Changyanning Syrup combined with Otilonium Bromide Tablets in treatment of irritable bowel syndrome. Methods Patients (92 cases) with irritable bowel syndrome in Henan Medical College Hospital Workers from April 2019 to August 2020 were randomly divided into control and treatment groups, and each group had 46 cases. Patients in the control group were po administered with Otilonium Bromide Tablets, 40 mg/time, three times daily. Patients in the treatment group were po administered with Changyanning Syrup on the basis of the control group, 10 mL/time, three times daily. Patients in two groups were treated for 4 weeks. After treatment, the clinical efficacies were evaluated, and the disappearance time of abdominal pain, abdominal distension, and diarrhea, the IBS-QOL scores, and the levels of IL-6, NRY, IL-18, VIP, CCK, and MTL in two groups were compared. Results After treatment, the total effective rates in the treatment group and control group were 93.48% and 78.26%, with significant difference between two groups (P<0.05). After treatment, the disappearance times of abdominal pain, abdominal distension, and diarrhea in the treatment group were shorter than those in the control group (P<0.05). After treatment, the IBS-QOL scores of two groups were significantly increased, and the difference was statistically significant (P<0.05). And the IBS-QOL scores of the treatment group were higher than those of the control group, and the difference was statistically significant (P<0.05). After treatment, the levels of IL-6 and IL-18 in two groups were significantly decreased, but the level of NRY in two groups was significantly increased (P<0.05). After treatment, the levels of IL-6 and IL-18 in the treatment group were lower than those in the control group, but the level of NRY in the treatment group was higher than that in the control group (P<0.05). After treatment, the levels of CCK in two groups were significantly increased, but the levels of VIP and MTL were significantly decreased (P<0.05). After treatment, the level of CCK in the treatment group was higher than that in the control group, while the levels of VIP and MTL in the treatment group were lower than those in the control group, and the difference was statistically significant (P<0.05). Conclusion Changyanning Syrup combined with Otilonium Bromide Tablets can improve the clinical efficacy of irritable bowel syndrome, improve the clinical symptoms, enhance the quality of life of patients, reduce inflammatory reaction, regulate gastrointestinal hormones, with good safety.

R975

河南省醫(yī)學(xué)科技攻關(guān)計(jì)劃聯(lián)合共建項(xiàng)目（2018020853）